FIDELITY ADVISOR SERIES VII
About this Fund
FIDELITY ADVISOR SERIES VII is a renowned mutual fund company that specializes in providing a wide range of investment solutions to its clients, catering to diverse financial goals and risk appetites. As a leading player in the asset management industry, the company offers a broad spectrum of mutual funds, including equity, debt, hybrid, and money market funds, among others. These funds are meticulously designed to provide investors with an opportunity to create a well-diversified portfolio, thereby minimizing risk and maximizing returns. By leveraging the expertise of seasoned investment professionals, FIDELITY ADVISOR SERIES VII employs a rigorous research-driven approach to identify lucrative investment opportunities, ensuring that its clients' wealth management needs are met with utmost precision. The company's investor-centric approach is reflected in its commitment to providing personalized investment solutions, tailored to meet the unique requirements of each client. Whether it is a seasoned investor or a novice, FIDELITY ADVISOR SERIES VII offers a comprehensive range of investment products and services, including Systematic Investment Plans (SIPs), that enable investors to achieve their long-term financial objectives. The company's robust distribution network and user-friendly online platform facilitate seamless transactions, allowing investors to easily manage their portfolios and stay abreast of market trends. With a strong focus on risk management and due diligence, FIDELITY ADVISOR SERIES VII has established itself as a trusted partner for investors seeking to navigate the complexities of the financial markets. FIDELITY ADVISOR SERIES VII's key strengths lie in its unwavering commitment to transparency, accountability, and customer satisfaction. The company's experienced team of investment managers and research analysts work in tandem to identify emerging trends and opportunities, ensuring that clients' investments are aligned with their risk profiles and financial goals. By adopting a disciplined investment approach, the company has consistently delivered strong performance across its range of mutual funds, thereby earning the trust and loyalty of its clients. As a result, FIDELITY ADVISOR SERIES VII has emerged as a preferred choice for investors seeking reliable and efficient wealth management solutions, providing them with the confidence to achieve their financial aspirations. With its rich legacy and unrelenting pursuit of excellence, the company continues to redefine the standards of asset management and investment services, solidifying its position as a leading mutual fund company in the industry.
Holdings
From latest SEC N-PORT filing · US-listed stocks only
| # | Security Name | CUSIP | Asset Type | Weight % | Value ($M) | Quantity |
|---|---|---|---|---|---|---|
| 1 | ORKA ORUKA THERAPEUTICS INC Since 2026-05-10 | 687604108 | Equity (Common) |
1.30%
|
$24.33 | 710,786 |
| 2 | ABBV ABBVIE INC Since 2026-05-10 | 00287Y109 | Equity (Common) |
16.61%
|
$309.89 | 1,389,580 |
| 3 | ALNY ALNYLAM PHARMACEUTICALS INC Since 2026-05-10 | 02043Q107 | Equity (Common) |
5.02%
|
$93.70 | 277,186 |
| 4 | AMGN AMGEN INC Since 2026-05-10 | 031162100 | Equity (Common) |
2.76%
|
$51.52 | 150,703 |
| 5 | RZLT REZOLUTE INC Since 2026-05-10 | 76200L309 | Equity (Common) |
0.36%
|
$6.63 | 1,985,100 |
| 6 | BIIB BIOGEN INC Since 2026-05-10 | 09062X103 | Equity (Common) |
2.84%
|
$52.91 | 294,100 |
| 7 | SLNO SOLENO THERAPEUTICS INC Since 2026-05-10 | 834203309 | Equity (Common) |
0.37%
|
$6.98 | 181,000 |
| 8 | CLDX CELLDEX THERAPEUTICS INC Since 2026-05-10 | 15117B202 | Equity (Common) |
0.36%
|
$6.78 | 275,652 |
| 9 | AVTX AVALO THERAPEUTICS INC Since 2026-05-10 | 05338F306 | Equity (Common) |
0.18%
|
$3.33 | 220,300 |
| 10 | CTMX CYTOMX THERAPEUTICS INC Since 2026-05-10 | 23284F105 | Equity (Common) |
0.41%
|
$7.68 | 1,350,251 |
| 11 | GILD GILEAD SCIENCES INC Since 2026-05-10 | 375558103 | Equity (Common) |
6.57%
|
$122.66 | 864,100 |
| 12 | CBIO CRESCENT BIOPHARMA INC Since 2026-05-10 | N/A | Equity (Common) |
0.13%
|
$2.41 | 251,090 |
| 13 | INO INOVIO PHARMACEUTICALS INC Since 2026-05-10 | 45773H409 | Equity (Common) |
0.08%
|
$1.44 | 883,081 |
| 14 | NTRA NATERA INC Since 2026-05-10 | 632307104 | Equity (Common) |
1.11%
|
$20.66 | 89,400 |
| 15 | QURE UNIQURE N.V. Since 2026-05-10 | N/A | Equity (Common) |
1.21%
|
$22.53 | 991,600 |
| 16 | TVTX TRAVERE THERAPEUTICS INC Since 2026-05-10 | 89422G107 | Equity (Common) |
0.50%
|
$9.36 | 301,200 |
| 17 | WVE WAVE LIFE SCIENCES LTD Since 2026-05-10 | N/A | Equity (Common) |
0.20%
|
$3.75 | 289,700 |
| 18 | VRDN VIRIDIAN THERAPEUTICS INC Since 2026-05-10 | 92790C104 | Equity (Common) |
3.15%
|
$58.82 | 1,782,464 |
| 19 | TENX TENAX THERAPEUTICS INC Since 2026-05-10 | 88032L605 | Equity (Common) |
0.22%
|
$4.04 | 322,600 |
| 20 | XENE XENON PHARMACEUTICALS INC Since 2026-05-10 | 98420N105 | Equity (Common) |
1.56%
|
$29.15 | 710,758 |
| 21 | SYRE SPYRE THERAPEUTICS INC Since 2026-05-10 | 00773J202 | Equity (Common) |
1.28%
|
$23.96 | 749,342 |
| 22 | MRNA MODERNA INC Since 2026-05-10 | 60770K107 | Equity (Common) |
1.59%
|
$29.72 | 674,300 |
| 23 | ANAB ANAPTYSBIO INC Since 2026-05-10 | 032724106 | Equity (Common) |
0.38%
|
$7.04 | 148,400 |
| 24 | ROIV ROIVANT SCIENCES LTD Since 2026-05-10 | N/A | Equity (Common) |
1.13%
|
$21.11 | 976,200 |
| 25 | RYTM RHYTHM PHARMACEUTICALS INC Since 2026-05-10 | 76243J105 | Equity (Common) |
0.69%
|
$12.94 | 126,200 |
| 26 | XFOR X4 PHARMACEUTICALS INC Since 2026-05-10 | 98420X202 | Equity (Common) |
0.27%
|
$4.96 | 1,341,800 |
| 27 | KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Since 2026-05-10 | N/A | Equity (Common) |
0.31%
|
$5.73 | 130,476 |
| 28 | COGT COGENT BIOSCIENCES INC Since 2026-05-10 | 19240Q201 | Equity (Common) |
3.83%
|
$71.40 | 1,988,418 |
| 29 | DNTH DIANTHUS THERAPEUTICS INC Since 2026-05-10 | 252828108 | Equity (Common) |
2.09%
|
$38.98 | 730,062 |
| 30 | TECX TECTONIC THERAPEUTIC INC Since 2026-05-10 | 878972108 | Equity (Common) |
0.13%
|
$2.42 | 120,995 |
| 31 | CRNX CRINETICS PHARMACEUTICALS INC Since 2026-05-10 | 22663K107 | Equity (Common) |
1.46%
|
$27.19 | 544,470 |
| 32 | STOK STOKE THERAPEUTICS INC Since 2026-05-10 | 86150R107 | Equity (Common) |
0.52%
|
$9.64 | 317,700 |
| 33 | ELVN ENLIVEN THERAPEUTICS INC Since 2026-05-10 | 29337E102 | Equity (Common) |
0.67%
|
$12.54 | 474,262 |
| 34 | DFTX DEFINIUM THERAPEUTICS INC Since 2026-05-10 | 24477V105 | Equity (Common) |
0.13%
|
$2.40 | 141,900 |
| 35 | PCVX VAXCYTE INC Since 2026-05-10 | 92243G108 | Equity (Common) |
2.29%
|
$42.66 | 796,329 |
| 36 | ANNX ANNEXON INC Since 2026-05-10 | 03589W102 | Equity (Common) |
0.34%
|
$6.27 | 1,005,200 |
| 37 | IRON DISC MEDICINE INC Since 2026-05-10 | 254604101 | Equity (Common) |
0.59%
|
$11.00 | 142,322 |
| 38 | KYMR KYMERA THERAPEUTICS INC Since 2026-05-10 | 501575104 | Equity (Common) |
0.90%
|
$16.84 | 231,700 |
| 39 | TNGX TANGO THERAPEUTICS INC Since 2026-05-10 | 87583X109 | Equity (Common) |
0.25%
|
$4.69 | 403,626 |
| 40 | SMMT SUMMIT THERAPEUTICS INC Since 2026-05-10 | 86627T108 | Equity (Common) |
0.26%
|
$4.77 | 329,400 |
| 41 | PRAX PRAXIS PRECISION MEDICINES INC. Since 2026-05-10 | 74006W207 | Equity (Common) |
1.45%
|
$27.13 | 86,400 |
| 42 | OLMA OLEMA PHARMACEUTICALS INC Since 2026-05-10 | 68062P106 | Equity (Common) |
1.08%
|
$20.13 | 782,800 |
| 43 | JBIO JADE BIOSCIENCES INC Since 2026-05-10 | 008064206 | Equity (Common) |
0.75%
|
$13.96 | 894,343 |
| 44 | JANX JANUX THERAPEUTICS INC Since 2026-05-10 | 47103J105 | Equity (Common) |
0.24%
|
$4.39 | 320,385 |
| 45 | NUVL NUVALENT INC Since 2026-05-10 | 670703107 | Equity (Common) |
2.27%
|
$42.42 | 412,264 |
| 46 | AMLX AMYLYX PHARMACEUTICALS INC Since 2026-05-10 | 03237H101 | Equity (Common) |
1.86%
|
$34.77 | 2,433,200 |
| 47 | ACLX ARCELLX INC Since 2026-05-10 | 03940C100 | Equity (Common) |
0.52%
|
$9.76 | 142,900 |
| 48 | MLYS MINERALYS THERAPEUTICS INC Since 2026-05-10 | 603170101 | Equity (Common) |
0.44%
|
$8.24 | 266,800 |
| 49 | ELVN ENLIVEN THERAPEUTICS INC Since 2026-05-10 | N/A | Equity (Common) |
0.00%
|
— | 739,725 |
| 50 | APGE APOGEE THERAPEUTICS INC Since 2026-05-10 | 03770N101 | Equity (Common) |
1.59%
|
$29.65 | 452,639 |
| 51 | RAPP RAPPORT THERAPEUTICS INC Since 2026-05-10 | 75383L102 | Equity (Common) |
0.22%
|
$4.18 | 156,946 |
| 52 | CGON CG ONCOLOGY INC Since 2026-05-10 | 156944100 | Equity (Common) |
0.69%
|
$12.96 | 248,900 |
| 53 | ELVN ENLIVEN THERAPEUTICS INC Since 2026-05-10 | N/A | Equity (Common) |
0.10%
|
$1.94 | 73,200 |
| 54 | ORKA ORUKA THERAPEUTICS INC Since 2026-05-10 | N/A | Equity (Common) |
0.05%
|
$0.91 | 26,600 |
| 55 | MBX MBX BIOSCIENCES INC Since 2026-05-10 | 55287L101 | Equity (Common) |
0.22%
|
$4.09 | 111,100 |
| 56 | ZBIO ZENAS BIOPHARMA INC Since 2026-05-10 | 98937L105 | Equity (Common) |
0.62%
|
$11.56 | 629,316 |
| 57 | UPB UPSTREAM BIO INC Since 2026-05-10 | 91678A107 | Equity (Common) |
1.15%
|
$21.48 | 691,003 |
| 58 | CBIO CRESCENT BIOPHARMA INC Since 2026-05-10 | N/A | Equity (Common) |
0.05%
|
$0.94 | 98,300 |
| 59 | MAZE MAZE THERAPEUTICS INC Since 2026-05-10 | 578784100 | Equity (Common) |
0.30%
|
$5.58 | 128,000 |
| 60 | ZBIO ZENAS BIOPHARMA INC Since 2026-05-10 | N/A | Equity (Common) |
0.08%
|
$1.58 | 86,234 |